Translate Bio Stock Forecast, Price & News

Translate Bio (NASDAQ:TBIO) Frequently Asked Questions

Is Translate Bio a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last twelve months. There are currently 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Translate Bio stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TBIO, but not buy additional shares or sell existing shares.
View analyst ratings for Translate Bio or view top-rated stocks.

What stocks does MarketBeat like better than Translate Bio?

Wall Street analysts have given Translate Bio a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Translate Bio wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Translate Bio's next earnings date?

Translate Bio is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Translate Bio.

How were Translate Bio's earnings last quarter?

Translate Bio, Inc. (NASDAQ:TBIO) issued its earnings results on Wednesday, August, 4th. The company reported $0.21 earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.44. The firm had revenue of $72.65 million for the quarter, compared to analyst estimates of $38.23 million. Translate Bio had a trailing twelve-month return on equity of 1.50% and a net margin of 17.97%.
View Translate Bio's earnings history.

What price target have analysts set for TBIO?

8 analysts have issued 12 month price objectives for Translate Bio's stock. Their forecasts range from $20.00 to $38.00. On average, they expect Translate Bio's share price to reach $27.50 in the next twelve months. This suggests that the stock has a possible downside of 26.4%.
View analysts' price targets for Translate Bio or view top-rated stocks among Wall Street analysts.

Who are Translate Bio's key executives?

Translate Bio's management team includes the following people:

• Ilan Danieli, Chief Executive Officer & Director
• Ahmed Zaki Sabet, Chief Operating Officer
• Carl R. Iberger, Chief Financial Officer
• Ayman A. Mohamed, Vice President-Research & Development
• Ori Karev, Chief Strategy Officer

What is Craig J. Tuttle's approval rating as Translate Bio's CEO?

13 employees have rated Translate Bio CEO Craig J. Tuttle on Glassdoor.com. Craig J. Tuttle has an approval rating of 5% among Translate Bio's employees. This puts Craig J. Tuttle in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Translate Bio's key competitors?

Some companies that are related to Translate Bio include Acceleron Pharma (XLRN), Novavax (NVAX), Neurocrine Biosciences (NBIX), CRISPR Therapeutics (CRSP), Exelixis (EXEL), Beam Therapeutics (BEAM), Twist Bioscience (TWST), Denali Therapeutics (DNLI), Kodiak Sciences (KOD), Fate Therapeutics (FATE), Halozyme Therapeutics (HALO), Vir Biotechnology (VIR), Abcam (ABCM), Adaptive Biotechnologies (ADPT) and Iovance Biotherapeutics (IOVA).
View all of TBIO's competitors.

What other stocks do shareholders of Translate Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Novavax (NVAX), Pfizer (PFE), Moderna (MRNA), Johnson & Johnson (JNJ), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and VBI Vaccines (vbiv).

When did Translate Bio IPO?

(TBIO) raised $100 million in an initial public offering (IPO) on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI acted as the underwriters for the IPO.

What is Translate Bio's stock symbol?

Translate Bio trades on the NASDAQ under the ticker symbol "TBIO."

What is Translate Bio's stock price today?

One share of TBIO stock can currently be purchased for approximately $37.36.

How much money does Translate Bio make?

Translate Bio has a market capitalization of $2.82 billion and generates $138.81 million in revenue each year. The company earns $-53.79 million in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does Translate Bio have?

Translate Bio employs 122 workers across the globe.

What is Translate Bio's official website?

The official website for Translate Bio is www.translate.bio.

Where are Translate Bio's headquarters?

Translate Bio is headquartered at 29 HARTWELL AVENUE, LEXINGTON MA, 02421.

How can I contact Translate Bio?

Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at (203) 787-7888.